SCHEMBL21174237

SCHEMBL21174237

Cn1cc(-c2cc(F)cc(CNC(=O)c3nccc4nc(CC5CC5)n(C)c34)c2)cn1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 6/20 0.47
▸ RORC P51449 1/20 0.39
▸ AURKB Q96GD4 2/20 0.39
▸ FGFR1 P11362 1/20 0.39
▸ FGFR2 P21802 1/20 0.39
▸ FGFR4 P22455 1/20 0.39
▸ FGFR3 P22607 1/20 0.39
▸ KDR P35968 1/20 0.39
▸ FLT3 P36888 1/20 0.39
▸ MAPK1 P28482 3/20 0.38
▸ CLK1 P49759 4/20 0.38
▸ KIT P10721 2/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ ROS1 P08922 1/20 0.37
▸ ALK Q9UM73 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21174380 0.97 MET (0.46) METRORCAURKBFGFR1FGFR2
SCHEMBL29634671 0.87 MET (0.47) METAURKBMAPK1CLK1KIT
SCHEMBL21174059 0.87 MET (0.47) METAURKBMAPK1CLK1KIT
SCHEMBL21174100 0.86 MET (0.47) METAURKBFGFR1FGFR2FGFR4
SCHEMBL21174158 0.83 MET (0.46) METAURKBMAPK1KITSMN1; SMN2
SCHEMBL21174316 0.82 MET (0.44) METAURKBMAPK1KIT
SCHEMBL21174242 0.82 MET (0.44) METRORCAURKBFGFR1FGFR2
SCHEMBL21174067 0.82 MET (0.43) METAURKBFGFR1FGFR2FGFR4
SCHEMBL21174397 0.81 MET (0.46) METAURKBMAPK1CLK1KIT
SCHEMBL21174285 0.81 MET (0.45) METAURKBMAPK1KITSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3514149-B1 HETEROCYCLIC AMIDE COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2022-05-18 — — EP disclosed
EP-3514149-B1 HETEROCYCLIC AMIDE COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2022-05-18 — — EP disclosed
US-10774083-B2 Heterocyclic amide compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-09-15 — — US disclosed
US-10774083-B2 Heterocyclic amide compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-09-15 — — US disclosed
US-20190241566-A1 HETEROCYCLIC AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-08 — — US disclosed
US-20190241566-A1 HETEROCYCLIC AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-08 — — US disclosed
EP-3514149-A1 HETEROCYCLIC AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2019-07-24 — — EP disclosed
EP-3514149-A1 HETEROCYCLIC AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2019-07-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190241566-A1 HETEROCYCLIC AMIDE COMPOUND PRSS8, PRSS1, PRSS2 MET 4152/4885RORC 4474/4885AURKB 2862/4885
US-10774083-B2 Heterocyclic amide compound PRSS8, PRSS1, PRSS2 MET 4152/4885RORC 4474/4885AURKB 2862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback